Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02016235 · ClinicalTrials.gov registry record · Phase 1

Role Of Phosphorus And FGF 23 In Patients With Dent Disease

A Phase 1 study, sponsored by Mayo Clinic.

Completed
Registry status
Phase 1
Development phase
30
Enrollment target

NCT02016235: Completed Phase 1 study, sponsored by Mayo Clinic.

NCT02016235 is a Phase 1 study that has completed, run by Mayo Clinic. The registered enrollment target is 30 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (50% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT02016235, a Phase 1 study, has completed, sponsored by Mayo Clinic.

COMPLETED
Registry status
Phase 1
Development phase
30 participants
Enrollment target

Study Summary

Patients with Dent disease have suppressed levels of FGF 23 which contributes to hypercalciuria, kidney stones, nephrocalcinosis and renal failure. Supplementation with phosphorus may reduce hypercalciuria.

Primary Outcome

Urine protein tests detect and/or measure protein being released into the urine. Normal urine protein elimination is less than 150 mg/day

Interventions

  • OTHER Observation
  • DRUG Phosphorus Supplement

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2014-09
Est. Completion 2019-01
Phase Phase 1
Mayo Clinic

2,844 total trials

What the finished NCT02016235 record still lists

NCT02016235 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (50% lower).

The record links to 0 conditions, and to 2 interventions - of which Observation is the first listed.

NCT02016235 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02016235 about?

NCT02016235 is a clinical study titled "Role Of Phosphorus And FGF 23 In Patients With Dent Disease". Patients with Dent disease have suppressed levels of FGF 23 which contributes to hypercalciuria, kidney stones, nephrocalcinosis and renal failure. Supplementation with phosphorus may reduce hypercalciuria.

What is the current status of trial NCT02016235?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2014-09. Estimated completion is 2019-01.

What interventions are being tested in trial NCT02016235?

The interventions under investigation include: Observation (OTHER), Phosphorus Supplement (DRUG).

Who is sponsoring clinical trial NCT02016235?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02016235's enrollment target sits among peer trials

30 1332nd of 2000 higher than 561 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02016235, the US trial registry maintained by the National Library of Medicine. NCT02016235 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.